Researchers identify target to help protect kidney patients' heart health

Blocking the receptor for proteins that constrict blood vessels reduces markers of heart-related problems in patients with chronic kidney disease (CKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings might be used to improve the health of patients with CKD, who most often die from cardiovascular disease.

Patients with CKD have an increased risk of developing , in part because kidney disease can cause their arteries to stiffen. This is thought to occur due to an impaired availability of a vasodilator—nitric oxide (NO)—in the blood. The protein endothelin-1 is a vasoconstrictor and opposes the actions of NO, suggesting that drugs that block its effects may help protect CKD patients' . One such drug is called sitaxentan, which blocks endothelin-1's receptor (called the ETA receptor).

Neeraj Dhaun, MD, PhD (University of Edinburgh, in Scotland) and his colleagues conducted a randomized, double-blind study in 27 patients with CKD to compare the effects of sitaxentan, nifedipine (a blood vessel relaxant), and placebo on , blood pressure, arterial stiffness, and various heart-related markers.

Among the major findings after six weeks of treatment:

  • Placebo and nifedipine did not affect three markers of heart-related problems: blood levels of uric acid; blood levels of asymmetric dimethylarginine (ADMA), a blocker of NO production; and urine levels of endothelin-1.
  • Sitaxentan treatment led to statistically significant reductions in all three of these markers.
  • Sitaxentan reduced proteinuria (an excess excretion of protein in the urine) to a significantly greater extent than nifedipine. Proteinuria is an indicator of .
  • Nifedpine and sitaxentan both reduced blood pressure to a similar extent.
"The current study shows, for the first time, that ETA receptor antagonism selectively lowers novel in patients with kidney disease independent of blood pressure. These effects were seen in patients already receiving optimal treatment," said Dr. Dhaun. "These findings suggest a potential role for ETA receptor antagonism in conferring additional longer-term cardiovascular and renal benefits in patients with kidney disease," he added.

More information: The article, entitled "Endothelin-A Receptor Antagonism Modifies Cardiovascular Risk Factors in CKD," will appear online: doi: 10.1681/2012040355

add to favorites email to friend print save as pdf

Related Stories

Gout drug benefits kidney disease patients

Jun 10, 2010

A drug commonly used to treat gout may help maintain kidney disease patients' health, according to an analysis appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The resear ...

Kidney drugs hampered by high blood phosphate

Aug 18, 2011

High blood phosphate levels can set chronic kidney disease (CKD) patients on a rapid path to kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). To mak ...

Recommended for you

Diseases of another kind

3 hours ago

The drought that has the entire country in its grip is affecting more than the color of people's lawns. It may also be responsible for the proliferation of a heat-loving amoeba commonly found in warm freshwater bodies, such ...

User comments